206 related articles for article (PubMed ID: 23453645)
1. Efficacy of two fluorescence in situ hybridization (FISH) probes for diagnosing malignant pleural effusions.
Rosolen DC; Kulikowski LD; Bottura G; Nascimento AM; Acencio M; Teixeira L; Vargas FS; Sales RK; Antonangelo L
Lung Cancer; 2013 Jun; 80(3):284-8. PubMed ID: 23453645
[TBL] [Abstract][Full Text] [Related]
2. [The negative enrichment by immunomagnetic beads for tumor cells from malignant pleural effusions].
Yang JJ; Xu XX; Min LF; Lin P; Qian GS
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Sep; 35(9):673-8. PubMed ID: 23158070
[TBL] [Abstract][Full Text] [Related]
3. Detection of hyperdiploid malignant cells in pleural effusions with chromosome-specific probes and fluorescence in situ hybridization.
Johnson TM; Kuffel DG; Dewald GW
Mayo Clin Proc; 1996 Jul; 71(7):643-8. PubMed ID: 8656705
[TBL] [Abstract][Full Text] [Related]
4. [Study on interphase cytogenetic abnormalities in malignant cells in pleural fluids from lung cancer cases].
Jia D; Zhang Z; Liu S; Cheng S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Aug; 17(4):244-7. PubMed ID: 10932006
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence in situ hybridization as adjunct to cytology improves the diagnosis and directs estimation of prognosis of malignant pleural effusions.
Han J; Cao S; Zhang K; Zhao G; Xin Y; Dong Q; Yan Y; Cui J
J Cardiothorac Surg; 2012 Nov; 7():121. PubMed ID: 23148562
[TBL] [Abstract][Full Text] [Related]
6. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
Matsumoto S; Nabeshima K; Kamei T; Hiroshima K; Kawahara K; Hata S; Marukawa K; Matsuno Y; Taguchi K; Tsujimura T
Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
[TBL] [Abstract][Full Text] [Related]
7. Detection of the human telomerase RNA component by in situ hybridization in cells from body fluids.
Nieh S; Chen SF; Fu E; Jan CI; Lee WH
Acta Cytol; 2005; 49(1):31-7. PubMed ID: 15717752
[TBL] [Abstract][Full Text] [Related]
8. Performance of the UroVysion
Rosolen DCB; Faria DK; Faria CS; Antonangelo L
Cancer Med; 2018 May; 7(5):1967-1977. PubMed ID: 29577646
[TBL] [Abstract][Full Text] [Related]
9. Detection of hyperdiploid malignant cells in body cavity effusions by fluoresence in situ hybridization on ThinPrep slides.
Florentine BD; Sanchez B; Raza A; Frankel K; Martin SE; Kovacs B; Felix JC
Cancer; 1997 Oct; 81(5):299-308. PubMed ID: 9349518
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy of human telomerase reverse transcriptase mRNA in malignant pleural effusions: A preliminary report for in situ hybridization detection.
Shu J; Sun GY; Liu AP; Liu J
Clin Chim Acta; 2007 Jun; 381(2):131-5. PubMed ID: 17399696
[TBL] [Abstract][Full Text] [Related]
11. Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.
Flores-Staino C; Darai-Ramqvist E; Dobra K; Hjerpe A
Lung Cancer; 2010 Apr; 68(1):39-43. PubMed ID: 19523712
[TBL] [Abstract][Full Text] [Related]
12. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.
Savic S; Franco N; Grilli B; Barascud Ade V; Herzog M; Bode B; Loosli H; Spieler P; Schönegg R; Zlobec I; Clark DP; Herman JG; Bubendorf L
Chest; 2010 Jul; 138(1):137-44. PubMed ID: 20139227
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma.
Veeramachaneni R; Nordberg ML; Shi R; Herrera GA; Turbat-Herrera EA
Diagn Cytopathol; 2003 Jun; 28(6):301-7. PubMed ID: 12768634
[TBL] [Abstract][Full Text] [Related]
14. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
15. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
[TBL] [Abstract][Full Text] [Related]
16. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
[TBL] [Abstract][Full Text] [Related]
17. Malignant cell detection by fluorescence in situ hybridization (FISH) in effusions from patients with carcinoma.
Fiegl M; Kaufmann H; Zojer N; Schuster R; Wiener H; Müllauer L; Roka S; Huber H; Drach J
Hum Pathol; 2000 Apr; 31(4):448-55. PubMed ID: 10821492
[TBL] [Abstract][Full Text] [Related]
18. Role of serial pleural biopsies in the diagnosis of pleural effusions.
Suri JC; Goel A; Gupta DK; Bhatia A
Indian J Chest Dis Allied Sci; 1991; 33(2):63-7. PubMed ID: 1791027
[TBL] [Abstract][Full Text] [Related]
19. The utility of fluorescence in-situ hybridization in the diagnosis of malignant pleural effusion.
Fiegl M
Curr Opin Pulm Med; 2005 Jul; 11(4):313-8. PubMed ID: 15928498
[TBL] [Abstract][Full Text] [Related]
20. Serous effusions in malignant lymphomas: a review.
Das DK
Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
